Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease:
Status:
Recruiting
Trial end date:
2022-09-15
Target enrollment:
Participant gender:
Summary
Noradrenergic system is involved in impulsivity in the general population and is altered in
Parkinson's disease (PD) in the early stages of the disease. Thus, targeting this system
could be of interest in impulse control disorder (ICD). Acting on the noradrenergic system is
possible using clonidine, an α2 adrenergic agonist largely used in hypertension treatment and
that induces a decrease of NADR release. Thus, our aim is to conduct a proof of concept study
evaluating the efficacy and safety of clonidine on ICD in PD. This study is a multicenter,
randomized, double-blind, placebo-controlled in parallel group clinical trial.